Invention Grant
- Patent Title: Isoxazoline hydroxamic acid derivatives as LpxC inhibitors
-
Application No.: US15454187Application Date: 2017-03-09
-
Publication No.: US09718792B2Publication Date: 2017-08-01
- Inventor: Jiping Fu , Xianming Jin , Subramanian Karur , Guillaume LaPointe , Patrick Lee , Zachary Kevin Sweeney
- Applicant: Novartis AG
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agent Michael G. Smith
- Main IPC: C07D417/10
- IPC: C07D417/10 ; C07D261/04 ; A61K31/42 ; C07D413/04 ; A61K31/4439 ; C07D413/10 ; A61K31/5377 ; A61K31/427 ; A61K31/422 ; A61K45/06
Abstract:
This invention pertains generally to compounds of Formula I and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention pertains to methods and compositions for treating infections caused by Gram-negative bacteria.
Public/Granted literature
- US20170174640A1 ISOXAZOLINE HYDROXAMIC ACID DERIVATIVES AS LpxC INHIBITORS Public/Granted day:2017-06-22
Information query
